scholarly journals Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention

2005 ◽  
Vol 26 (22) ◽  
pp. 2396-2403 ◽  
Author(s):  
Peter R. Sinnaeve ◽  
John Simes ◽  
Salim Yusuf ◽  
Jyotsna Garg ◽  
Shamir Mehta ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Acute Coronary Syndromes ◽  
Coronary Intervention ◽  
Thrombin Inhibitors ◽  
Direct Thrombin Inhibitors ◽  
Percutaneous Coronary ◽  
Coronary Syndromes

Bivalirudin and argatroban

2018 ◽  
Author(s):  
Davide Capodanno
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Coronary Intervention ◽  
Thrombin Inhibitors ◽  
Direct Thrombin Inhibitors ◽  
Heparin Induced Thrombocytopenia ◽  
St Segment Elevation ◽  
St Segment ◽  
Percutaneous Coronary ◽  
Coronary Syndromes

The central role of thrombin in the process of clot formation makes it an important therapeutic target. Heparin is a potent anticoagulant, but has a number of limitations, in that—for example—it does not bind clot-bound thrombin, activates platelets, and may determine heparin-induced thrombocytopenia (HIT). Bivalirudin and argatroban, which belong to the class of intravenous direct thrombin inhibitors, overcome many of the limitations of heparin. Bivalirudin is currently indicated for patients undergoing percutaneous coronary intervention, patients with non-ST-segment elevation acute coronary syndromes planned for urgent or early intervention, and patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Both argatroban and bivalirudin can be used as an alternative to heparin in patients with HIT and HIT-thrombosis syndrome. This chapter describes the current clinical applications of bivalirudin and argatroban.

Bivalirudin and argatroban

ESC CardioMed ◽  
2018 ◽  
pp. 255-259
Author(s):  
Davide Capodanno
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Coronary Intervention ◽  
Thrombin Inhibitors ◽  
Direct Thrombin Inhibitors ◽  
St Segment Elevation ◽  
St Segment ◽  
Percutaneous Coronary ◽  
Coronary Syndromes ◽  
Important Therapeutic Target

The central role of thrombin in the process of clot formation makes it an important therapeutic target. Heparin is a potent anticoagulant, but has a number of limitations, in that—for example—it does not bind clot-bound thrombin, activates platelets, and may determine heparin-induced thrombocytopenia (HIT). Bivalirudin and argatroban, which belong to the class of intravenous direct thrombin inhibitors, potentially overcome many of the limitations of heparin. Bivalirudin is currently indicated as an alternative to unfractionated heparin for selected patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention, and patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Both argatroban and bivalirudin can be used as an alternative to heparin in patients with HIT and HIT-thrombosis syndrome. This chapter describes the current clinical applications of bivalirudin and argatroban.

Early versus delayed percutaneous coronary intervention in patients with non-ST elevation acute coronary syndromes

2016 ◽  
Vol 27 (5) ◽  
pp. 344-349 ◽  
Author(s):  
Matias B. Yudi ◽  
Andrew E. Ajani ◽  
Nick Andrianopoulos ◽  
Stephen J. Duffy ◽  
Omar Farouque ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Acute Coronary Syndromes ◽  
Coronary Intervention ◽  
Percutaneous Coronary ◽  
Coronary Syndromes ◽  
St Elevation
Sign in / Sign up

Export Citation Format

Share Document